Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment;Bazický fibroblastový růstový faktor (bFGF) a cévní endotelový růstový faktor (VEGF) jsou zvýšeny v plazmě periferní krve nemocných s chronickou lymfocytární leukemií a klesají po intenzivní léčbě obsahující fludarabin

Vnitrni Lekarstvi

Volumn 53, Issue 11, 2007, Pages 1171-1176

  Smolej, L ^a   Andrys C ^b   Krejsek, J ^b   Belada, D ^a   Zak P ^a   Siroky O ^a   Maly J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; bFGF; Chronic lymphocytic leukemia; Fludarabine; Prognosis; Treatment; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLOPHOSPHAMIDE; CYTOKINE; EDETIC ACID; FLUDARABINE; RITUXIMAB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIDARABINE;

EID: 37149034102     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763
3. Pour L, Hájek R, Büchler T et al. Angiogeneze a antiangiogenní léčba u nádorů. Vnitř Lék 2004; 50(12): 930-938.
4. Smolej L, Benešová P. Význam angiogeneze u maligních nádorů. Acta Medica (Hradec Králové) Suppl 2005; 48: 69-72.
5. Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
6. Moehler TM, Ho AD, Goldschmidt H et al. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003; 45: 227-244.
7. Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26: 351-362.
8. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167.
9. Perez-Atayde AR, Sallan SE, Tedrow U et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
10. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-1210.
11. Papajík T, Jarošová M, Pikalová Z et al. Chronická B-lymfocytární leukemie. Část II: Diagnostická kritéria a význam stanovení individuální prognózy nemocného. Trans Hemat dnes 2006; 12: 132-139.
12. Kay NE, Bone ND, Tschumper RC et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16: 911-919.
13. Molica S, Vitelli G, Levato D et al. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer 2002; 86: 31-35.
14. Menzel T, Rahman Z, Calleja E et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996; 87: 1056-1063.
15. Konig A, Menzel T, Lynen S et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B-cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997; 11: 258-265.
16. Ferrajoli A, Manshouri T, Estrov Z et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001; 7: 795-799.
17. Gora-Tybor J, Blonski JZ, Robak T Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma 2002; 49: 145-148.
18. Auguste P, Javerzat S, Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 200; 314: 157-166.
19. Šimíčková M, Dubská L, Kocáková I et al. Angiogeneze a antiangiogenní terapie se zaměřením na cirkulující vaskulá rní endotelový růstový faktor (VEGF). Klin Onkol 2006; 19: 212-216.
20. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Nat Rev Drug Discov 2004; 3: 391-400.
21. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
22. Rai KR. A critical analysis of staging in CLL In: Gale RP, Rai KR (eds). Chronic Lymphocytic Leukemia. Recent Progress and Future Direction. New York (NY): AR Liss 1987: 253.
23. Duensing S, Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood 1995; 85: 1978-1980.
24. Molica S, Vitelli G, Levato D et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 107: 605-610.
25. Bairey O, Zimra Y, Shaklai M et al. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 113: 400-406.
26. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003; 12: 167-171.
27. Gora-Tybor J, Blonski JZ, Robak T. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw 2005; 16: 41-46.
28. Wolowiec D, Dybko J, Wrobel T et al. Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm 2006; 3: 1-6.
29. Krejci P, Dvorakova D, Krahulcova E. FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemia. Leukemia 2001; 15: 228-237.
30. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343-350.
31. Webb NJ, Bottomley MJ, Watson CJ et al. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998; 94: 395-404.
32. George ML, Eccles SA, Tutton MG et al. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6: 3147-3152.
33. Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-964.
34. Vacca A, Iurlaro M, Ribatti D et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999; 94: 4143-4155.
35. Kerbel KS, Viloria-Petit A, Klement G et al. "Accidental" anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248-1257.
36. Smolej L, Andrys C, Pekova S et al. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. Haematologica 2006; 91: 1432-1433.
37. Chanan-Khan A, Miller KC, Takeshita K et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348-3352.
38. Chanan-Khan A. Targeting the microenvironment: a new treatment paradigm for chronic lymphocytic leukaemia. Haematologica Reports 2006; 2: 22-27.